{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:09:57Z","timestamp":1790186997622,"version":"4.1.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2018,7,3]]},"DOI":"10.3233\/jad-171157","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T18:35:02Z","timestamp":1528828502000},"page":"689-707","source":"Crossref","is-referenced-by-count":21,"title":["Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer\u2019s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study"],"prefix":"10.1177","volume":"64","author":[{"given":"Stephen P.","family":"Salloway","sequence":"first","affiliation":[{"name":"Brown Medical School, Butler Hospital, Providence, RI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research and Treatment, Brigham and Women\u2019s Hospital, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, University College London, Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[{"name":"Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Rofael","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzeera","family":"Ketter","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wang","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enchi","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Carr","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Black","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Robert","family":"Brashear","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC, Pennington, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-171157_ref1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.3233\/JAD-171157_ref2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/srep01302","article-title":"Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation","volume":"3","author":"Miles","year":"2013","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-171157_ref3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-171157_ref5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12883-017-0850-1","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease: A meta-analysis of randomized controlled trials","volume":"17","author":"Abushouk","year":"2017","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-171157_ref6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12603-009-0059-0","article-title":"Evolution of Abeta42 and Abeta40 levels and Abeta42\/Abeta40 ratio in plasma during progression of Alzheimer\u2019s disease: A multicenter assessment","volume":"13","author":"Blennow","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.3233\/JAD-171157_ref7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-171157_ref8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-171157_ref9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-171157_ref10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-171157_ref11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-171157_ref12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-171157_ref13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-171157_ref14","doi-asserted-by":"crossref","first-page":"S44.002","DOI":"10.1212\/WNL.80.7_supplement.S44.002","article-title":"Clinical correlates of amyloid-related imaging abnormalities (ARIA) in phase 3 studies of bapineuzumab in Alzheimer\u2019s disease (AD) (S44.002)","volume":"80","author":"Sperling","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-171157_ref15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ana.22315","article-title":"Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42","volume":"68","author":"Schott","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-171157_ref16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(03)14469-8","article-title":"Change in rates of cerebral atrophy over time in early-onset Alzheimer\u2019s disease: Longitudinal MRI study.","volume":"362","author":"Chan","year":"2003","journal-title":"Lancet"},{"key":"10.3233\/JAD-171157_ref17","doi-asserted-by":"crossref","unstructured":"Sperling RA , Jack CR Jr , Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3, 111cm133.","DOI":"10.1126\/scitranslmed.3002609"},{"key":"10.3233\/JAD-171157_ref18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737175.2014.945522","article-title":"Efficacy and safety studies of gantenerumab in patients with Alzheimer\u2019s disease","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-171157_ref20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-171157_ref21","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-171157_ref22","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMc1402193","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"de la Torre","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMc1402193","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"Laske","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1304839","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-171157_ref26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: Stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-171157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:22Z","timestamp":1777370842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-171157"}},"subtitle":[],"editor":[{"given":"Katherine","family":"Bangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":26,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-171157","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]}}}